Alphatec Holdings, Inc. filings document the reporting record of a spine-focused medical technology company. Its Form 8-K disclosures include quarterly and annual operating results, surgical and EOS revenue commentary, non-GAAP profitability measures, preliminary financial information and related press-release exhibits.
The company’s regulatory filings also cover material financing agreements, including senior secured credit facilities, revolving borrowing capacity, term-loan arrangements and references to convertible senior notes. Proxy and governance filings document director elections, board composition, executive and director compensation, equity awards, committee matters and other shareholder voting disclosures.
Alphatec Holdings (ATEC) is a spine-focused medical technology company aiming to “be the standard bearer in spine” through clinically distinct, procedure-based solutions. It designs and sells integrated platforms spanning implants, biologics, neuromonitoring, imaging, planning software and emerging navigation/robotics to improve predictability and reproducibility in spine surgery.
For the year ended December 31, 2025, Alphatec generated $764.2 million in total revenue, up $152.6 million, or 25%, from $611.6 million in 2024, driven by broader adoption of approach-specific procedures such as PTP, LTP and deformity offerings. Surgical volume grew 22% and average revenue per surgery increased 4% versus 2024, reflecting deeper surgeon usage as its portfolio expands.
The company’s strategy centers on three pillars: creating clinical distinction through continuous innovation (including the InformatiX platform with EOS imaging and EOS Insight software, SafeOp neuromonitoring and Valence navigation/robotics), compelling surgeon adoption via its ATEC Experience training programs, and elevating distribution by building an exclusive, clinically sophisticated sales network in the U.S. and targeted international markets.
Alphatec Holdings (ATEC) reported strong 2025 growth but remains loss-making on a GAAP basis. Full-year 2025 total revenue rose 25% to $764 million, with GAAP gross margin of 70%. Non-GAAP net income reached $8 million and adjusted EBITDA was $93 million, a 12% margin.
Fourth-quarter 2025 revenue was $213 million with adjusted EBITDA of $33 million, or 16% of revenue, and free cash flow of $8 million. Despite this, GAAP net loss for 2025 was $143 million. Cash and cash equivalents were $161 million at year-end.
For full-year 2026, Alphatec expects revenue to approximate $890 million, about 17% growth, including $805 million of surgical revenue and $85 million of EOS revenue. The company raised adjusted EBITDA guidance to about $134 million, or 15% margin, and anticipates generating at least $20 million of free cash flow.
Alphatec Holdings executive Craig E. Hunsaker exercised multiple stock options and increased his direct ownership. On February 12, 2026, he exercised options for 31,710 shares at $1.93, 120,248 shares at $1.68, 78,249 shares at $2.69, and 20,969 shares at $3.09 per share.
The exercise was handled on a cashless basis, with the issuer withholding 41,105 shares to cover the exercise price and issuing 210,071 shares of common stock to Hunsaker. Following these transactions, he directly owned 1,383,096 shares of Alphatec common stock.
Alphatec Holdings, Inc. executive David Sponsel, EVP of Sales, reported selling 60,425 shares of common stock on February 5, 2026 at a weighted average price of $13.79 per share. The filing states the sales were made under a Rule 10b5-1 trading plan adopted on June 12, 2025 to cover certain tax withholding obligations arising from vested restricted stock units.
After this transaction, Sponsel beneficially owns 349,500 shares of Alphatec common stock, including shares acquired through the company’s employee stock purchase plan and reflecting the forfeiture of some previously reported restricted stock units that did not meet performance criteria.
Alphatec Holdings insider David Sponsel has filed to sell 60,425 shares of common stock under Rule 144. The shares, to be sold through Morgan Stanley Smith Barney on NASDAQ around February 5, 2026, have an aggregate market value of $849,575.50 based on the filing.
The securities to be sold were acquired on February 1, 2026 via 40,418 Performance Stock Units and 20,007 Restricted Stock Units granted by the issuer. The notice also reports past 3‑month sales of 21,106 and 988 common shares, including 10b5‑1 plan sales for David Sponsel.
Alphatec Holdings, Inc. executive Craig E. Hunsaker, EVP, People & Culture, reported selling 37,358 shares of ATEC common stock on February 3, 2026 at a weighted average price of $14.71 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2025 to cover tax withholding from vested restricted stock units. After the sale, Hunsaker beneficially owned 1,173,025 common shares.
ATEC filed a notice under SEC Rule 144 for a planned sale of restricted or control shares. The filing shows an intended sale of 37,358 common shares on Nasdaq through Merrill Lynch, with an aggregate market value of 548,196 and 148,550,185 common shares outstanding.
The securities relate to common shares acquired on 02/01/2026 via an RSU transaction, with payment on 02/03/2026 noted as "sold to cover." In the prior three months, Craig Hunsaker sold 32,584 common shares on 12/10/2025 for gross proceeds of 676,889.
Alphatec Holdings, Inc. furnished a current report to share that it has issued a press release with selected preliminary, unaudited financial information for the year ended December 31, 2025. The company notes that its year-end financial closing process is not yet complete, so the figures in the press release are estimates and may change, potentially in a material way, as closing adjustments are recorded. The press release is included as Exhibit 99.1, and the company specifies that this information is being furnished rather than filed under securities laws, which limits how it is treated for liability and incorporation into other filings.
Alphatec Holdings, Inc. CEO Miles Patrick reported selling 100,000 shares of common stock on January 5, 2026 at a weighted average price of $21.01 per share. The sale was effected under a Rule 10b5-1 trading plan adopted on June 3, 2025, with individual trade prices ranging from $20.46 to $21.35.
After this transaction, Patrick beneficially owned 5,135,398 Alphatec common shares directly, plus 10,900 shares held indirectly through an IRA and 250,000 shares held indirectly through MOM, LLC as of the reported date.
Alphatec Holdings, Inc. reported an insider stock sale by a company officer serving as EVP, People & Culture. On 12/10/2025, the officer sold 32,584 shares of common stock at $20.84 per share. Following this transaction, the insider directly owns 1,256,558 shares of Alphatec common stock.